LAM IPM wound gel
This article was originally published in The Gray Sheet
Executive Summary
LAM Pharmaceutical's sodium hyaluronate product, 510(k) cleared April 15, has an 88% effectiveness rate "in creating the necessary environment for wound healing of refractory (hard to heal) leg and foot ulcers," the firm says. The Lewiston, New York firm will launch the gel on June 3. The device is indicated for over-the-counter use on minor abrasions and cuts and for use under the supervision of a health professional for exuding wounds such as leg, pressure and diabetic ulcers...
You may also be interested in...
Biogen Sees Improving Momentum In Slow Leqembi Launch
Sales of the company’s new drugs have a lot of growing to do to make up for older products’ declines, but Biogen highlighted signs of strength for new launches in its Q1 report.
Vivalink Partners With Rett Syndrome Research Trust To Accelerate Research In Rare Disease
Vivalink will provide ECG wearable technology to monitor patients in RSRT’s Vibrant study, which is aimed at assessing autonomic dysfunction in children with Rett syndrome.
Cidara Offloads Rezzayo, Will Focus On Universal Flu Preventative
Cidara conferred global rights to its novel antifungal to marketing partner, Mundipharma, while reacquiring a flu prophylaxis it licensed to J&J in 2021 and gaining $240m in new funding to back development.